Intravenous iron therapy for treating patients with iron deficiency anaemia during the perioperative period of gynecological malignancy.

Anaemia is a common phenomenon in patients with malignant gynecological tumors. The occurrence of anaemia in the perioperative period leads to an increased probability of blood transfusion, increased surgical complications,poor wound healing, prolonged hospitalization, increased medical costs, and increased mortality. Intravenous iron, which is known for its rapid onset and lack of gastrointestinal side effects, has become increasingly prevalent in clinical practice. A total of 300 patients with gynaecological malignancies were admitted to The First Affiliated Hospital,Hengyang Medical School,University of South China between January, 2019 and December , 2021. Anaemia was assessed during routine blood tests by measuring red blood cell (RBC) counts, hemoglobin (Hb) levels, haematocrit (HCT) values, mean corpuscular volume (MCV), and mean corpuscular hemoglobin (MCH). The postoperative blood transfusion rate, transfusion volume, infection rate, and hospitalization duration were also recorded and comparisons were made between the control and treatment groups.Our study showed that preoperative intravenous iron injection can effectively increase haemoglobin levels in patients with anemia caused by gynecological cancer, reduces the probability of perioperative blood transfusion., decreases postoperative complications and infection rates, shortens hospital stays, and improves short-term prognosis in patients. We concluded that intravenous iron presents is a valuable clinical option for addressing perioperative anaemia in patients with gynecologic malignancies.